A newly published study of patients receiving immunotherapy for advanced mesothelioma draws attention to a part of cancer care that matters alongside tumor response: recognizing serious complications and coordinating treatment when hospitalization becomes necessary.
Researchers at Queen Elizabeth Hospital Birmingham in the United Kingdom examined 24 patients treated with nivolumab and ipilimumab. Twenty patients experienced at least one hospital admission, and six experienced grade 3 or higher immune-related adverse events.
These figures describe a small group at one hospital. They do not mean that 83% of all mesothelioma patients receiving immunotherapy will require hospitalization.
What did the November 14 study examine?
Researchers Reshma David and Rehmatullah Khan reviewed records from April 2021 through October 2025. Twenty-three patients had pleural mesothelioma and one had peritoneal mesothelioma. The investigators documented 36 hospital admission episodes among 20 patients.
According to the published study, 16 hospitalized patients had admissions attributed to immunotherapy-related adverse effects; admissions in four other patients were attributed to disease-related or other complications. Six patients experienced severe immune-related adverse events, classified as grade 3 or higher. Hospital admission and severe immune-related toxicity are different measures and should not be confused.
The authors reported median progression-free survival of 4.5 months and median overall survival of 9.5 months in this group. These numbers are not forecasts for an individual patient, and the study had no randomized comparison group.
What side effects should patients recognize?
Nivolumab and ipilimumab are immune checkpoint inhibitors. They help the immune system attack cancer cells but can also cause inflammation in healthy organs. Possible problems include lung inflammation, diarrhea or intestinal inflammation, liver or kidney inflammation, skin reactions, and hormone-related complications.
New or worsening breathlessness, persistent diarrhea, cough, rash, marked fatigue, weakness or other unexplained changes should be discussed promptly with the treating oncology team. Symptoms may be caused by immunotherapy, the cancer itself, infection or another condition; patients should not try to determine the cause on their own.
Severe breathing difficulty, chest pain, sudden confusion, seizures or loss of consciousness require immediate emergency medical attention. Immune-related side effects can occur during treatment or after treatment has ended. Patients should follow their oncology team's instructions and should not independently stop or change prescribed cancer treatment.
What if urgent care is needed near home?
Mesothelioma patients may receive treatment at a specialist cancer center but live far from that hospital. A local emergency department may be the most appropriate place for immediate evaluation when serious symptoms arise.
Patients and caregivers can ask their oncology team what information to keep readily available, including:
- Names of immunotherapy medicines and dates of recent doses.
- Contact details for the treating oncologist and cancer center, including after-hours instructions.
- A current medication list and relevant medical history.
- Any treatment alert card or written emergency guidance supplied by the care team.
Emergency clinicians should be told about immune checkpoint inhibitor treatment even if it has ended.
What did the researchers learn about support services?
The Birmingham center provided access to a 24-hour oncology telephone helpline and specialist nursing support. Even so, admissions occurred. The investigators did not establish how often patients contacted the helpline before admission or whether earlier intervention could have prevented any hospitalization.
They identified further study of immunotherapy triage and supportive care as a potential area for improvement. Their findings do not prove that a particular hospitalization was avoidable.
How does this compare with larger research?
A separate French real-world study involving 204 patients receiving nivolumab and ipilimumab reported that 34.3% were hospitalized for treatment toxicity and 24.2% experienced grade 3 or higher immune-related adverse events. It reported median overall survival of 20.2 months.
The hospitalization percentages from the two studies are not directly comparable: the Birmingham figure covers admissions for multiple causes, while the French figure concerns hospitalization for treatment toxicity. The studies also differed in patient populations and methods. Their different survival figures do not establish that immunotherapy worked better at one center than another.
The randomized CheckMate 743 trial previously established a survival benefit for nivolumab plus ipilimumab compared with chemotherapy in certain patients with previously untreated, unresectable pleural mesothelioma. This small observational study does not overturn that evidence; it adds information about treatment experiences in routine care.
Questions patients can ask before immunotherapy
- Which new symptoms should prompt an immediate call to the oncology team?
- Which symptoms require emergency evaluation?
- How can the care team be reached after hours?
- What should a local emergency department know about treatment?
- Can complications arise after the last dose?
- How would treatment-related complications be evaluated and managed?
What this means for mesothelioma patients and families
The study is a reminder that successful cancer care involves more than selecting an anticancer drug. It also requires recognizing complications, responding to symptoms and coordinating care among clinicians. It does not establish that immunotherapy should be avoided or that hospitalizations can necessarily be prevented.
For additional background, see H&S's Mesothelioma Treatment Options and Finding a Mesothelioma Specialist.
Original research and medical sources
- David and Khan, Cureus, November 14, 2026 (PubMed)
- Assié and colleagues, French real-world immunotherapy study (PubMed)
- National Cancer Institute: Immunotherapy Side Effects
- National Cancer Institute: Malignant Mesothelioma Treatment
Medical information notice: This report is for general education. Humpleby & Strauss, P.C. is a law firm and does not provide medical treatment. Patients should consult qualified clinicians about individual care and should not change treatment based on this article.